Recursion Pharmaceuticals, Inc. (RXRX) 28th Annual Needham Growth Conference January 16, 2026 12:45 PM EST
Company Participants
Ben Taylor – CFO & President of Recursion UK
Conference Call Participants
Ryan MacDonald – Needham & Company, LLC, Research Division
Presentation
Ryan MacDonald
Needham & Company, LLC, Research Division
Hello, everyone, and welcome to this next session on the final day of the 28th Annual Needham Growth Conference. I’m Ryan MacDonald, and I lead Needham’s Healthcare Technology research efforts. And in this session, I’m pleased to be joined by Recursion Pharmaceuticals CFO, Ben Taylor. Ben, thanks for joining me.
Ben Taylor
CFO & President of Recursion UK
Pleasure to be here. Thanks, Ryan.
Ryan MacDonald
Needham & Company, LLC, Research Division
Yes. Thanks for coming. All right. So for those who are joining us, first of all, thanks for joining us. And second, we are going to have about a 35-minute fireside chat conversation here. I’ve got a number of questions and topics that Ben and I are going to run through. But if any of you have questions for Ben that are listening in, please put into the chat box, and we’ll make sure to get that asked and answered if there’s some time at the end. But with that, Ben, let’s get started. So for folks in the audience who might be newer to the Recursion story, I’ll give you us an overview of the business.
Question-and-Answer Session
Ben Taylor
CFO & President of Recursion UK
Sure, of course. Well, and I think one of the really important parts is actually taking a step back and thinking about why we’re here at all. So there are well over 1,000 biotech companies out there, and we actually have quite a different mandate for most of them. So a lot of our foundational investors, so the Baillie Gifford, the SoftBanks, and the [indiscernible] of
